Celgene Corp. (NASDAQ:CELG)
2017 Stifel Healthcare Conference
November 14, 2017 02:45 PM ET
Scott Smith – President and COO
Terrie Curran – President, Inflammation and Immunology
Tom Shrader – Stifel Nicolaus
Okay. Welcome back, everybody. So, this is the Stifel Healthcare Conference. I’m Tom Shrader, one of the biotech analysts. Next, we have Celgene. Quite a treat. It’s quite a complicated story. So, the more time you can get with them, I think must feel the better. We have Scott Smith, the COO; Terrie Curran, Head of I&I; and Lisa Hayes from IR. And I’m glad to have all the audience questions you want. My plan is to more or less step through the therapeutic areas and try to see what we can learn. It will be a little bit pipeline-focused. I’m sure you’re tired of questions about what you’re going to use your balance sheet and for what so I won’t ask any of those.
So, we’ll start with multiple myeloma, a field you own but you may not own forever or you’re certainly working hard to make that not the case. Maybe just your thoughts on how you see the field evolving because one of the things that you have a huge blockbuster that you won’t have forever, but the plan is not really to replace it with another improved version. It is to get deeper into the biology. So just your thoughts about how that field will unfold.
So, thank you, and good afternoon to everybody here. Let me start off more broadly first and then I’ll try to go more specific to answer your question around multiple myeloma. One of the questions that I get a lot and I had a lot at this particular conference is tell me what things look like 2020 and beyond.
And I think integral of that is this idea of what we’re going to do in the multiple myeloma marketplaces 2020 and beyond. And one of the things, to me there’s the three basic areas of focus as we move into 2020 and beyond and the first being the multiple myeloma marketplace. And it’s one that we obviously have a very strong position in and the one that we’re very involved with.
And we want to make sure that we’re in a position to move forward the strategy with a number of assets to have the potential to transform the treatment space of multiple myeloma 2020 and beyond.
There are a couple different legs to that stool right now and there’s the BCMA assets including Bluebird bb2121, a BCMA focused CAR T product. We’ve got a bio-specific antibody focused on BCMA that required for acquisition…